Indegene Q2 FY27 Earnings Call — Analysis (NSE: INDGN)
Indegene posted Q2FY27 revenue of ₹1,122.3 Cr (+39.5% YoY, +5.6% QoQ) and EBITDA margin of 16.7%, reiterating plans to exit Q4 at 19%+ EBITDA margin as GenAI deal ramps accelerate.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
Q2FY27 Revenue ₹1,122.3 Cr ( +39.5% YoY ) . New guidance — Q4FY27 or Q1FY28 client revenue cohort threshold $25 million-plus . New story: Client base diversification and breadth .
Results
Revenue reached ₹1,122.3 Cr (+39.5% YoY, +5.6% QoQ) while PAT stood at ₹1,123 Cr (+10% YoY) with EBITDA margin at 16.7% absorbing a 150 bps annual wage hike.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹1,122.3 Cr | +39.5% | yoy · Q2FY27 |
| Revenue | ₹1,122.3 Cr | +5.6% | qoq · Q2FY27 |
| EBITDA | ₹187.3 Cr | +32% | yoy · Q2FY27 |
| EBITDA Margin | 16.7% | none · Q2FY27 · absorbed 150bps wage hike | |
| Profit Before Tax | ₹147.4 Cr | none · Q2FY27 | |
| Profit After Tax | ₹112.3 Cr | +10% | yoy · Q2FY27 |
| Cash and Investments | ₹1,389.6 Cr | point_in_time · Q2FY27 · Sep-2026 |
Guidance
Management reiterated targeting quarterly EBITDA margins of 19%+ by Q4FY27 alongside higher organic full-year growth than FY26.
What management committed to
- Improved yields and lower amortization will expand PBT margin by 90 to 95 basis points in the coming quarters. — 90-95 basis points, H2FY27
- Tectonic quarterly run rate will cross $2 million in the coming quarters. — >$2 million per quarter, Q4FY27
- The customer that dropped below $25 million will return to the $25 million-plus cohort within the next 2 to 3 quarters. — $25 million-plus, Q4FY27 or Q1FY28
Key themes
GenAI-led upstream expansion and margin expansion
How the narrative shifted
- Measured AI enterprise adoption as opportunity: Management now treats enterprise AI adoption as an accelerating tailwind, citing the Indegene Digital Summit where the question shifted from 'if' to 'how to scale'.
- Client base diversification and breadth: Broadening is now backed by strong growth in the top 5 and top 20 segments alongside continued expansion in new logos, proving the strategy scales.
- Outcome-aligned revenue model moving upstream: Outcome-based revenue (60% of revenue) is now the standard for new deals, validated by Agentic AOR, Tectonic expansions, and the $10M omnichannel deal.
- Gen AI as structural tailwind not threat: Gen AI is now fully embedded across the stack (Cortex, Tectonic, Agentic AOR), creating a widening productivity moat and enabling wins across the value chain.
- Margin recovery after deliberate front-loaded investments: Confidence from the prior call is now backed by evidence: the Q2 wage hike was absorbed with a stable margin, confirming the investment thesis.
- Pharma industry robust growth and regulatory stability: Management presented an unusually strong alignment of tailwinds (capital, approvals, pipeline, AI) as a once-in-several-years opportunity for Indegene's model.
- BioPharm integration exceeding expectations: BioPharm is no longer a stand-alone acquisition; its data and omnichannel capabilities are embedded in Indegene's platform and driving wins across the enterprise.
- Integrated AI-led content ecosystem: Management is guiding that the boundaries between Tectonic, Agentic AOR, and production are blurring into a single AI-led content model spanning the entire commercialization value chain.
Operational commentary
- Won 9 deals with ACV >$1M, including 3 large deals (one $5M+ and two $3M-$5M), primarily in Enterprise Commercial.
- Expanded GenAI Tectonic model to Canada with largest client; contracted run-rate crossed $2M/quarter (Q2 actuals $1.7M).
- Agentic AOR (Agency of Record) pilot converted to full engagement (> $1M) with a top 20 pharma client for molecule launch concepting.
- BioPharm integration completed first year, unlocking $1.5M annual cost savings reinvested into expanding GTM team from 3 to 9; on track for max earnout based on >15% CY26 revenue growth.
- Trailing 12-month revenue per employee increased to $79,600 from ~$69,000 a year ago, driven by platform delivery and outcome-based pricing.
Analyst Q&A
Q. Why is Tectonic ramp-up at the largest client slow while scope is expanding?
Explained that central enterprise procurement teams sign centralized contracts, but decentralized regional and therapeutic brand teams take time to change operational habits; this organizational dynamic is normal and expected to resolve.
Q. What is the theoretical cap for outcome-aligned revenue beyond the current 60%+ share?
Declined to specify a numeric ceiling, citing ongoing AI workflow transition and retained FTE custodian layers, but confirmed recent deal wins are overwhelmingly outcome-based.
Q. Are frontier AI models (e.g., Anthropic partnerships with pharma) a competitive threat?
Noted frontier models lack domain workflows, knowledge graphs, and execution layers; Indegene partners with tech ecosystems rather than competing, as technology is the easier part compared to pharma workflow redesign.
Research and educational content only. Not investment advice.